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Introduction
Glucagon is a polypeptide hormone that plays a key role in the regulation of  glucose homeostasis (1–3). It is 
secreted from α cells of  the pancreatic islets of  Langerhans to increase blood glucose levels in times of  fasting 
and to counteract the actions of  insulin in the liver and other tissues (1–3). Accumulating evidence suggests 
that α cell dysfunction contributes to impaired glucose homeostasis in type 1 and 2 diabetes (1, 2, 4). At pres-
ent, the role of  glucagon secretion from α cells in the pathophysiology of  diabetes is not well understood. 
Thus, a better understanding of  α cell physiology and pathophysiology is likely to provide novel insights into 
impaired glucose homeostasis characteristic for type 1 and 2 diabetes and to identify novel targets for the 
development of  antidiabetic drugs.
In vitro studies suggest that α cell glucagon can modulate β cell function (2, 5). However, it remains 
unknown whether this intraislet cross-talk plays a role in regulating glucose homeostasis in vivo, primarily due 
to the lack of suitable animal models. To address this issue, we established what we believe to be a novel mouse 
line that enabled us to acutely suppress glucagon secretion from pancreatic α cells in a drug-dependent fashion 
in vivo. This mouse line, referred to as α-GiD herein, expressed an inhibitory designer GPCR in α cells only. 
This designer GPCR represents a DREADD (designer receptor exclusively activated by a designer drug) that is 
selectively coupled to inhibitory G proteins of the Gi family (6–8). Importantly, this DREADD, referred to as 
GiD herein, can be activated by a small-molecule compound called clozapine N-oxide (CNO), an agent that is 
otherwise pharmacologically inert (6–8). This mouse model provided us with the opportunity to acutely inhibit 
the activity of α cells and dramatically lower plasma glucagon levels in vivo.
Here we show that intraislet glucagon signaling is required for the efficient release of  insulin in vivo 
and for the proper regulation of  blood glucose homeostasis. Strategies aimed at enhancing intraislet gluca-
gon signaling could prove useful to promote insulin secretion for therapeutic purposes.
Glucagon, a hormone released from pancreatic α cells, plays a key role in maintaining proper glucose 
homeostasis and has been implicated in the pathophysiology of diabetes. In vitro studies suggest 
that intraislet glucagon can modulate the function of pancreatic β cells. However, because of the 
lack of suitable experimental tools, the in vivo physiological role of this intraislet cross-talk has 
remained elusive. To address this issue, we generated a mouse model that selectively expressed 
an inhibitory designer GPCR (Gi DREADD) in α cells only. Drug-induced activation of this inhibitory 
designer receptor almost completely shut off glucagon secretion in vivo, resulting in markedly 
impaired insulin secretion, hyperglycemia, and glucose intolerance. Additional studies with 
mouse and human islets indicated that intraislet glucagon stimulates insulin release primarily by 
activating β cell GLP-1 receptors. These findings strongly suggest that intraislet glucagon signaling 
is essential for maintaining proper glucose homeostasis in vivo. Our work may pave the way toward 
the development of novel classes of antidiabetic drugs that act by modulating intraislet cross-talk 
between α and β cells.
Results
Generation of  mice expressing the GiD designer receptor selectively in pancreatic α cells. To generate the α-GiD 
mutant mice, we used a recently developed mouse strain in which the expression of  GiD (also known 
as hM4Di) (6, 9) is dependent on the activity of  Cre recombinase (Rosa26-LSL-hM4Di mice) (10). We 
crossed Rosa26-LSL-hM4Di mice with a recently developed, improved Gcg-CreERT2 mouse line that express-
es CreERT2 following tamoxifen (TMX) treatment from the endogenous preproglucagon locus without 
disrupting preproglucagon expression (11). This latter mouse line exhibits high recombination efficien-
cy in pancreatic α cells and enteroendocrine L cells (11). The resulting mutant mice carrying both the 
Rosa26-LSL-hM4Di and Gcg-CreERT2 alleles were injected i.p. with TMX for 6 consecutive days (2 mg per 
day). TMX-injected Rosa26-LSL-hM4Di mice lacking the Gcg-CreERT2 transgene served as control animals 
throughout the study. All mouse strains were maintained on a C57BL/6 background.
Because of  the different kinetics of  cell turnover between intestinal L cells and pancreatic α cells, we 
were able to obtain mutant mice that expressed GiD selectively in α cells. This was achieved by simply 
waiting approximately 4 weeks following the last TMX injection, allowing the Cre-modified L cells to be 
replaced by WT L cells originating from the crypts (11).
To confirm that the GiD receptor was selectively expressed in islets of  TMX-treated Rosa26-LSL-hM-
4Di Gcg-CreERT2 mice, we carried out immunoblotting studies with cell lysates prepared from pancreatic 
islets and several other tissues, including ileum and colon, where most GLP-1–expressing L cells are local-
ized. GiD protein was detected by an anti-HA antibody that recognized the HA-epitope tag fused to the 
extracellular N-terminus of  GiD (10). Supplemental Figure 1 (supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.127994DS1) shows that the GiD construct was selectively 
expressed in pancreatic islets of  TMX-treated Rosa26-LSL-hM4Di Gcg-CreERT2 mice but not in control mice.
To demonstrate that the GiD receptor was selectively expressed by pancreatic α cells, we carried out 
immunofluorescence staining experiments using slices prepared from pancreatic islets of  TMX-treated 
Rosa26-LSL-hM4Di Gcg-CreERT2 and control mice. We found that approximately 96% of  glucagon-express-
ing islet cells (α cells) coexpressed HA-tagged GiD protein (Figure 1A, top). In contrast, GiD expression 
was not detectable in islet cells that expressed insulin (Figure 1B, top) or other islet cells not expressing 
glucagon. No GiD expression was observed with slices from pancreatic islets prepared from control mice 
(Figure 1, bottom left). For this analysis, nearly 1000 islet cells from 3 Rosa26-LSL-hM4Di Gcg-CreERT2 mice 
and 3 control mice were studied.
These observations clearly indicate that the TMX-treated Rosa26-LSL-hM4Di Gcg-CreERT2 mice selec-
tively express the GiD DREADD in pancreatic α cells. For the sake of  brevity, we refer to these mutant 
mice as α-GiD mice throughout.
In vivo metabolic studies with control and α-GiD mice. We subjected the α-GiD mice, along with their con-
trol littermates, to a series of  in vivo metabolic tests. Unless indicated otherwise, adult male mice that 
were at least 12 weeks old were used for all experiments. The 2 mouse strains did not show any significant 
differences in body weight (Supplemental Figure 2A). α-GiD and control mice that had free access to food 
or that had been fasted overnight for 12 hours showed comparable plasma glucagon, plasma insulin, and 
blood glucose levels (Supplemental Figure 2, B–D).
To activate the GiD receptor in α cells of  α-GiD mice, we injected α-GiD mice with a single dose of  
CNO (1 mg/kg i.p.). Strikingly, CNO treatment of  either fasted or freely fed α-GiD mice caused dramatic 
reductions (by ~90%) in plasma glucagon levels over the entire 30-minute observation period (Figure 2, A 
and D). This effect was accompanied by pronounced reductions in plasma insulin levels (Figure 2, B and 
E). In control mice that did not express the GiD receptor, the CNO injection had no significant effect on 
plasma insulin levels (Figure 2, B and E) but caused a modest decrease in plasma glucagon levels (Figure 
2, A and D). To rule out the possibility that this latter response was caused by an off-target effect of  CNO, 
we carried out analogous studies with WT C57BL/6 mice. We found that CNO (1 mg/kg i.p.) or saline 
treatment of  fasted WT mice caused reductions in plasma glucagon levels that were similar in magnitude to 
those observed with CNO-treated α-GiD control mice (Supplemental Figure 3A). This observation strongly 
suggests that the i.p. injection procedure itself  can lower plasma glucagon levels, at least under the exper-
imental conditions used in this study. CNO or saline treatment of  WT mice had no significant effect on 
plasma insulin levels (Supplemental Figure 3B).
The CNO-induced reductions in plasma glucagon and insulin levels displayed by the α-GiD mice 
had little effect on blood glucose levels during the first 30 minutes after CNO injection, as compared 
with CNO-injected control mice (Figure 2, C and F). Following CNO (1 mg/kg i.p.) treatment of  
α-GiD mice, plasma glucagon and insulin levels remained greatly reduced for at least 2 hours (Sup-
plemental Figure 4, A and B). Interestingly, α-GiD mice, but not their control littermates, displayed 
significantly increased blood glucose levels 60–120 minutes after CNO injection (Supplemental Figure 
4C), most likely due to the long-lasting decrease in plasma insulin levels. CNO treatment of  α-GiD 
mice and their control littermates had little or no effect on plasma GLP-1, GIP, and somatostatin 
(SST) levels (Supplemental Figure 5).
All experiments described above were carried out with male mice. Supplemental Figure 6 shows that 
CNO treatment (1 mg/kg i.p.) of  female α-GiD mice caused a dramatic reduction in plasma glucagon and 
a significant decrease in plasma insulin levels, as observed with male α-GiD mice. Moreover, blood glucose 
levels were significantly elevated 2 hours after CNO treatment of  female α-GiD mice, as compared with 
their control littermates (Supplemental Figure 6C).
We next subjected α-GiD mice and control littermates to glucose and insulin tolerance tests (Figure 3). 
Injection of  mice with glucose alone (2 g/kg i.p.) caused similar increases in blood glucose levels in α-GiD 
mice and control littermates (Figure 3A). In contrast, coinjection of  glucose (2 g/kg i.p.) with CNO (1 mg/
kg i.p.) caused significantly greater blood glucose excursions in α-GiD mice, as compared with control lit-
termates (Figure 3B), indicating that activation of  α cell GiD receptors causes impaired glucose tolerance. 
This decrease in glucose tolerance was associated with a dramatic reduction in plasma glucagon levels and 
a greatly reduced insulin response, as compared with coinjected control animals (Figure 3, C and D). One 
possible explanation for this finding is that the release of  intraislet glucagon is required for the ability of  
glucose to stimulate insulin release from β cells with high efficacy.
Acute injection of  mice with insulin alone (0.75 U/kg i.p; insulin tolerance test) caused comparable 
decreases in blood glucose levels in α-GiD mice and control littermates (Figure 3E). Coinjection of  insulin 
(0.75 U/kg i.p.) with CNO (1 mg/kg i.p.) caused a slight increase in insulin sensitivity only at one single 
time point (45 minutes after injection) (Figure 3F). At the same time, insulin/CNO coinjection almost 
completely shut down glucagon secretion in α-GiD mice (Figure 3G). In contrast, the same treatment 
caused an increase in plasma glucagon levels in control mice (Figure 3G). Coinjection of  insulin and 
CNO caused similar increases in plasma insulin levels in α-GiD mice and control littermates (Figure 3H).
Perifusion studies with pancreatic islets prepared from control and α-GiD mice. On the basis of  the outcome 
of  in vivo metabolic studies, we hypothesized that the impairments in glucose tolerance and glucose-stim-
ulated insulin secretion (GSIS) observed after CNO treatment of  α-GiD mice (Figure 3, B and D) were 
caused by the relative lack of  intraislet glucagon. To further test this hypothesis, we carried out a series of  
perifusion studies using islets prepared from control and α-GiD mice.
We initially monitored glucagon and insulin release in control islets at low and high glucose con-
centrations (3 mM and 12 mM, respectively). We also quantitated glucagon and insulin release after 
addition of  a physiological amino acid mixture (AAM) that promotes glucagon release from α cells 
(1–14). As expected, increasing the glucose concentration from 3 to 12 mM led to a decrease in gluca-
gon secretion but to an increase in insulin release (Figure 4, A and B). Addition of  the AAM mixture 
at 12 mM glucose led to a very robust increase in both glucagon and insulin secretion (Figure 4, A and 
B). The addition of  CNO (10 μM) to the perifusion fluid had no significant effect on glucagon or insulin 
release from control islets (Figure 4, A and B).
A completely different pattern emerged when we studied glucagon and insulin secretion from islets 
prepared from α-GiD mice (α-GiD islets) (Figure 4, C and D). In the presence of  CNO (10 μM), glucagon 
release was significantly reduced, independent of  the glucose concentration in the perifusion medium. 
Most notably, the very pronounced increase in glucagon secretion seen after addition of  AAM in the 
absence of  CNO was nearly abolished in α-GiD islets in the presence of  CNO (Figure 4C). The glucose/
AAM-induced decreases in glucagon secretion caused by CNO treatment were accompanied by marked 
reductions in insulin release (Figure 4D). Thus, these in vitro data strongly support our hypothesis that 
glucagon released from α cells acts in a paracrine fashion on β cells and that this cross-talk is required for 
the ability of  β cells to stimulate insulin secretion with high efficacy.
To further support the conclusion that the insulin secretion deficit observed with CNO-treated α-GiD 
islets was indeed caused by reduced intraislet glucagon signaling, we carried out the “rescue experiment” 
shown in Figure 5. Specifically, we perifused α-GiD islets with 12 mM glucose and AAM, either in the 
absence or the presence of  CNO (10 μM), as described above. As expected, insulin release was significantly 
reduced in the CNO-treated α-GiD islets under these experimental conditions (Figure 5). We next added 
glucagon (10 nM) to the islet preparations 15 minutes after costimulation of  islets with 12 mM glucose and 
AAM. Strikingly, the addition of  glucagon to the CNO-treated α-GiD islets fully restored normal insulin 
secretion, as compared with glucagon-treated α-GiD islets that had not been exposed to CNO (Figure 5). 
This observation strongly supports the concept that the impairment in insulin secretion displayed by the 
CNO-treated α-GiD islets was caused by the relative lack of  intraislet glucagon.
Glucagon released from α cells acts primarily on β cell GLP-1 receptors to greatly enhance insulin secretion. Pan-
creatic β cells are known to express glucagon and GLP-1 receptors, 2 GPCRs known to enhance GSIS 
(15). In fact, GLP-1 receptor agonists such as exendin-4 are in therapeutic use to promote insulin secre-
tion in patients suffering from type 2 diabetes (16, 17). Previous studies have shown that glucagon is able 
to activate both of  these receptors, although with different potencies (5, 18). In contrast to glucagon, the 
levels of  the active form of  GLP-1 are extremely low or undetectable in mouse pancreatic islets (5, 19).
Based on these considerations, we next tested the hypothesis that glucagon released from α cells acts on 
β cell glucagon and/or GLP-1 receptors to promote the secretion of  insulin. Specifically, we subjected islets 
prepared from WT C57BL/6 mice to same experimental protocol as described above for α-GiD islets (Fig-
ure 6). WT islets were perifused in the presence of  exendin(9–39) (Ex-9; 1 μM), a selective GLP-1 receptor 
antagonist (20, 21); adomeglivant (Ado; also known as LY2409021; 1 μM), a selective glucagon receptor 
antagonist (22, 23); or a mixture of  Ex-9 and Ado (1 μM each).
Figure 1. Selective expression of GiD in pancreatic α cells. Immunofluorescent staining of slices from pancreatic islets of α-GiD and control mice. Note that 
the GiD receptor carried an N-terminal HA-tag, allowing its localization with an anti-HA antibody. Nuclei were stained blue with DAPI mounting medium. (A) 
Slices from α-GiD mice (i–iv) and control littermates (v–viii) were stained for HA-GiD (Alexa Fluor, green) and glucagon (Alexa Fluor, red). (B) Slices from α-GiD 
mice (i–iv) and control littermates (v–viii) were stained for HA-GiD (Alexa Fluor, green) and insulin (Alexa Fluor, red). These representative images show that 
the GiD receptor is not expressed in control islets but is selectively expressed by α cells of islets from α-GiD mice. Original magnification, ×40.
Perifusion experiments showed that the glucose/AAM-induced changes in glucagon secretion were not 
affected by the presence of  Ex-9, Ado, or a combination of  these 2 antagonists (Figure 6, A, C, and E, 
and Supplemental Figure 7, A, C, and E). In striking contrast, glucose- and glucose/AAM-induced insulin 
secretion responses were greatly reduced when WT islets were perifused in the presence of  Ex-9 (Figure 6B 
and Supplemental Figure 7B). The presence of  Ado in the perifusion fluid had no significant effect on glu-
cose/AAM-induced increases in insulin release (Figure 6D and Supplemental Figure 7D). When perifusion 
studies were carried out in the simultaneous presence of  Ex-9 and Ado, glucose/AAM-stimulated insulin 
secretion was also strongly reduced (Figure 6F and Supplemental Figure 7F). The Ex-9/Ado-induced inhi-
bition of  glucose/AAM-stimulated insulin release appeared slightly more robust than that observed after 
perifusion of  WT islets with Ex-9 alone (Figure 6, B and F, and Supplemental Figure 7, B and F).
We also carried out perifusion experiments with human islets. These studies were done in the contin-
ued presence of  physiological AAM to promote glucagon release and to more closely mimic physiological 
conditions (14). The addition of  Ex-9 (1 μM) had no significant effect on glucagon release throughout the 
perifusion period (Figure 6G). In contrast, GSIS was significantly reduced when Ex-9 was added prior to 
stimulation with 16.7 mM glucose (Figure 6H). GSIS was reduced to a similar extent when human islets 
were exposed to a mixture of  Ado and Ex-9 (1 μM each) (Supplemental Figure 8).
Discussion
In the present study, we generated a mouse model that allowed us to acutely and selectively inhibit gluca-
gon release from pancreatic α cells in vivo. Specifically, we created mutant mice that selectively expressed 
an inhibitory designer GPCR (GiD) in α cells only (α-GiD mice).
It is known that glucagon (preproglucagon) is also expressed in the brain, particularly in the brainstem 
and hypothalamus (24). We were unable to detect the expression of  the GiD designer receptor in the hypo-
thalamus of  α-GiD mice (Supplemental Figure 1). It is therefore unlikely that brain expression of  GiD 
affects the outcome of  the reported in vivo data.
Figure 2. Acute activation of α cell GiD almost completely shuts down glucagon secretion in vivo. All mice (α-GiD mice and control littermates) were 
injected i.p. with CNO (1 mg/kg) at time “0.” (A–C) Studies with fasted mice (overnight fast for 12 hours). (D–F) Studies with freely fed mice. Plasma gluca-
gon (A and D), plasma insulin (B and E), and blood glucose (C and F) levels were measured at the indicated time points using blood collected from the tail 
vein. All experiments were carried out with male littermates that were at least 12 weeks old. Data are given as mean ± SEM (α-GiD: n = 13; control: n = 6). 
*P < 0.05; **P < 0.01 (mixed-effects repeated-measures ANOVA for after injection differences).
CNO treatment of α-GiD mice led to a drastic reduction in plasma glucagon levels in α-GiD mice (by 
~90%) (Figure 2, A and D). Surprisingly, the resulting low circulating plasma glucagon levels did not result in 
hypoglycemia, even in CNO-treated α-GiD mice that had been fasted overnight (Figure 2C). The CNO-induced 
hypoglucagonemia was accompanied by a pronounced reduction in plasma insulin levels (Figure 2, B and E), 
most likely due to impaired intraislet glucagon signaling, as suggested by in vitro islet perifusion studies (see 
below). The ability of hypoinsulinemia to promote hepatic glucose production (25) provides a possible explana-
tion for the observation that hypoglucagonemia did not cause hypoglycemia. It is also possible that euglycemia 
was maintained by compensatory, glucagon-independent mechanisms, including increased activity of hepatic 
adrenergic receptors (26) or enhanced hepatic corticosterone signaling (25). Consistent with this concept, adult 
Gcg mutant mice lacking functional glucagon had normal blood glucose levels, even after a 16-hour fast (27).
Based on the in vivo phenotypes displayed by the α-GiD mice, we hypothesized that the impairments 
in glucose tolerance and GSIS observed with CNO-treated α-GiD mice (Figure 3, B and D) might be due 
to decreased intraislet glucagon levels. To test this hypothesis, we performed a series of  perifusion stud-
ies using islets prepared from control and α-GiD mice. These studies, complemented by hormone release 
experiments carried out with human islets, indicated that efficient GSIS requires intraislet glucagon that 
acts primarily on β cell GLP-1 receptors (Figures 4 and 6). On the other hand, β cell glucagon receptors, 
which, like GLP-1 receptors, preferentially couple to Gs (15), only make a minor contribution to this gluca-
gon effect (Figures 4 and 6). One likely reason for this observation is that GLP-1 receptors are expressed at 
10- to 20-fold higher levels than glucagon receptors in mouse islets (28). The results of  the islet perifusion
studies are summarized in a schematic fashion in Figure 7.
What is the likely mechanism through which activation of  the GiD receptor suppresses α cell activity? 
Under physiological conditions, SST released from pancreatic δ cells strongly inhibits glucagon secretion 
from pancreatic α cells by activating SST-2 receptors (29). Activation of  α cell SST-2 receptors leads to 
the opening of  G protein–gated inwardly rectifying K+ channels, thus suppressing electrical activity and 
directly inhibiting exocytosis (30). Like the GiD designer receptor, which is derived from the human M4 
muscarinic receptor (6), the SST-2 receptor subtype is selectively linked to G proteins of  the Gi family (29). 
It is therefore likely that CNO-mediated activation of  GiD inhibits α cell activity in a similar fashion.
Figure 3. Acute activation of α cell GiD causes impaired glucose tolerance in α-GiD mice. (A–D) Mice that had been fasted overnight were injected with 
glucose (2 g/kg i.p.), either in the absence or presence of CNO (1 mg/kg i.p). (A) i.p. glucose tolerance test (IGTT) in the absence of CNO. (B) IGTT in the 
presence CNO. (C) Plasma glucagon levels during IGTT in the presence of CNO. (D) Plasma insulin levels during IGTT in the presence of CNO. (E–H) Mice that 
had been fasted for 4 hours were injected with insulin (0.75 U/kg i.p.), either in the absence or presence of CNO (1 mg/kg i.p). (E) Insulin tolerance test (ITT) 
in the absence of CNO. (F) ITT in the presence CNO. (G) Plasma glucagon levels during ITT in the presence of CNO. (H) Plasma insulin levels during ITT in the 
presence of CNO. Blood samples were collected from the tail vein. All experiments were carried out with male littermates that were 20–30 weeks old. Data 
are given as mean ± SEM (α-GiD: n = 13; control: n = 6). *P < 0.05; **P < 0.01 (mixed-effects repeated-measures ANOVA for after injection differences).

In a related study, Svendsen et al. (5) used isolated perfused mouse pancreata to study the poten-
tial role of  intraislet glucagon signaling. This preparation offers the advantage that it maintains the 
local cytoarchitecture and microvasculature, ensuring normal flux of  hormones, metabolites, and other 
agents between the different cell types. To acutely eliminate glucagon secretion from α cells, the authors 
used a mouse model that allows diphtheria toxin (DT) to selectively destroy proglucagon-producing α 
cells (DT-Gcg mice). In these DT-Gcg mice, glucagon output was drastically decreased, as compared 
with control mice. Strikingly, GSIS was also greatly reduced in pancreatic preparations from DT-Gcg 
mice (5). In agreement with this observation, we found that CNO-mediated suppression of  glucagon 
secretion in α-GiD pancreatic islets also caused a significant decrease in GSIS. By using pancreatic 
preparations from either whole-body or β cell–specific glucagon and GLP-1 receptor–KO mice, Svend-
sen et al. concluded that the of  loss of  either glucagon or GLP-1 receptors alone has no effect on 
insulin secretion but that only combined blockade of  both receptors causes reduced insulin release (5). 
In contrast, we clearly demonstrated that Ex-9, a highly selective GLP-1 receptor antagonist, strongly 
reduced insulin release in perifused pancreatic islets prepared from WT mice (Figure 6B). In contrast, 
Ado, a selective glucagon receptor blocker, did not affect insulin release in WT islets under the same 
experimental conditions (Figure 6D). It is likely that different experimental conditions (e.g., the use of  
perfused pancreata vs. perifused islets) and the use of  different mouse models are responsible for the 
discrepant conclusions regarding the relative roles of  β cell GLP-1 and glucagon receptors in regulating 
insulin release stimulated by intraislet glucagon.
Very recently, Capozzi et al. published a study that also explored the importance of  α to β cell 
communication (31). Interestingly, the authors showed that Ex-9 reduced glucagon-stimulated insulin 
secretion by approximately 65% in WT islets and by approximately 80% in islets prepared from mice 
selectively lacking the glucagon receptor in β cells. This observation is in good agreement with our in 
vitro data, indicating that the GLP-1 receptor is the main mediator of  glucagon-induced insulin release. 
Capozzi et al. (31) also demonstrated that amino acid–induced (arginine and glutamine) insulin secre-
tion was nearly abolished after simultaneous blockade of  glucagon and GLP-1 receptors. We obtained 
similar findings when we treated perifused WT islets with either Ex-9 alone or with a mixture of  Ex-9 
and a glucagon receptor antagonist (Figure 6, B and F), strongly suggesting that β cell GLP-1 receptors 
are the major mediator of  amino acid–induced insulin secretion and that β cell glucagon receptors also 
contribute to this response (Figure 7).
While we used a chemogenetic approach to suppress glucagon release from α cells, Capozzi et al. (31) 
carried out studies with islets prepared from mice deficient in the proglucagon gene (Gcg). These mutant 
animals are unable to produce any of  the Gcg gene products, including glucagon and GLP-1. Consistent 
with our data involving the chemogenetic silencing of  α cells, islets from Gcg mutant mice displayed dra-
matically reduced insulin secretion after treatment with amino acids or a high concentration of  glucose 
(GSIS). Taken together, both studies strongly suggest that glucagon (or glucagon plus GLP-1) release is 
required for efficient nutrient-induced insulin secretion from WT islets.
Under our experimental conditions, maximum glucagon levels in the perifusion fluid reached 40–80 
pM. The intraislet concentration of  glucagon is probably considerably higher than this value. Previous 
work has shown that glucagon can activate GLP-1 receptors expressed in cultured cells at concentrations 
lower than 1 nM (5, 32). These findings strongly suggest that intraislet glucagon levels are sufficiently high 
to activate β cell GLP-1 receptors in mouse islets.
Activation of  glucagon and GLP-1 receptors leads to the activation of  the stimulatory G protein, Gs, 
which in turn activates adenyl cyclase, resulting in increased intracellular cAMP levels (15). Interestingly, 
Capozzi et al. (31) found that cAMP levels were significantly reduced in β cells after simultaneous blockade 
Figure 4. Activation of GiD in perifused α-GiD islets causes strong reductions in glucagon and insulin secretion. Islets from control and α-GiD 
mice were perifused with the indicated glucose concentrations (3 mM and 12 mM; G3 and G12, respectively) in the presence (red curve) or absence 
(black curve) of CNO (10 μM). In the bar graphs, hormone secretion during specific time intervals was expressed as the average of all values mea-
sured during a particular perifusion period: G3 ± CNO, 20–40 minutes; G12 ± CNO, 40–60 minutes; G12 + AAM ± CNO, 60–80 minutes. (A) Glucagon 
secretion from control islets. (B) Insulin secretion from control islets. (C) Glucagon secretion from α-GiD islets. (D) Insulin secretion from α-GiD 
islets. The amounts of secreted glucagon and insulin were normalized to islet DNA content. All islets were prepared from male littermates that 
were 14–20 weeks old. Data are given as mean ± SEM (3 or 4 perifusions with 50 islets per perifusion chamber; islets from 2 mice were pooled per 
perifusion experiment). *P < 0.05; **P < 0.01 (2-tailed Student’s t test). AAM, amino acid mixture (see Methods for details).
of  glucagon and GLP-1 receptors, suggesting that glucagon/GLP-1 action on β cells maintains cAMP lev-
els within a range required for efficient insulin release.
As discussed above, our data, together with 2 related recent studies (5, 31), strongly support the 
concept that glucagon released from α cells acts in a paracrine fashion primarily on β cell GLP-1 recep-
tors to promote GSIS. However, we cannot completely rule out the possibility that the GiD-mediated 
suppression of  α cell activity affects β cell function by additional, as yet unknown, paracrine factors or 
mechanisms. For example, Rodriguez-Diaz et al. (33) demonstrated that human α cells contain ace-
tylcholine that is released when glucose levels are low. However, in contrast to human α cells, acetyl-
choline release is undetectable in mouse α cells (33), suggesting that changes in acetylcholine secretion 
from α cells do not contribute to the reductions in GSIS observed after GiD-mediated silencing of  α 
cells in mice.
To further support the conclusion that the insulin secretion deficit observed with CNO-treated 
α-GiD islets was indeed caused by reduced intraislet glucagon signaling, we carried out the rescue 
experiment shown in Figure 5. We demonstrated that the addition of  glucagon (10 nM) to CNO-treat-
ed α-GiD islets fully restored normal insulin secretion, providing additional evidence that the impair-
ment in insulin secretion displayed by the CNO-treated α-GiD islets was caused by the relative lack of  
intraislet glucagon.
We found that the CNO-mediated decrease in glucagon secretion observed with α-GiD islets was rel-
atively small at both G3 and G12 in the absence of  amino acids, a major stimulus for glucagon secretion 
(Figure 4C). In contrast, CNO treatment of  fed or fasted α-GiD mice led to a dramatic reduction in plasma 
glucagon levels in vivo, accompanied by a pronounced decrease in plasma insulin levels (Figure 2). In the 
in vivo experiments, pancreatic islets are always exposed to a physiological mixture of  glucagon-releasing 
amino acids, providing a possible explanation for the differences in glucagon and insulin release observed 
with CNO-treated α-GiD islets (in the absence of  amino acids) versus CNO-treated α-GiD mice.
In a previous study, Pedersen et al. (34) injected genetically engineered mice with DT to selectively 
ablate pancreatic α cells. In contrast to our findings with CNO-treated α-GiD mice, the DT-treated mutant 
mice showed normal i.p. glucose tolerance. One possible explanation for these discrepant findings is that 
CNO treatment of  α-GiD mice led to a dramatic reduction in glucagon release within minutes, while the 
DT-mediated ablation of  α cells occurred over a considerably longer time period, allowing for the potential 
emergence of  compensatory processes. Moreover, we found that the GiD designer receptor was expressed 
in virtually all α cells. In contrast, Pedersen et al. observed a marked but not complete reduction in the 
number of  α cells (34).
Figure 5. Glucagon restores normal insulin release in CNO-treated α-GiD islets. Islets from α-GiD mice were perifused with the indicated glucose concen-
trations (3 mM and 12 mM; G3 and G12, respectively) in the presence (red curve) or absence (black curve) of CNO (10 μM). At 45 minutes (15 minutes after 
the addition of AAM), glucagon (10 nM) was added to the perifusion fluid. In the bar graphs, insulin secretion during specific time intervals was expressed 
as the average of all values measured during a particular perifusion period: G3, 0–15 minutes; G12, 15–30 minutes; G12+AAM, 30–45 minutes; G12+AAM+-
glucagon, 45–65 minutes. Insulin secretion was normalized to islet DNA content. All islets were prepared from male littermates that were 20–24 weeks 
old. Data are given as mean ± SEM (4 perifusions with 50 islets per perifusion chamber; islets from 2 mice were pooled per perifusion experiment). *P < 
0.05 (2-tailed Student’s t test). AAM, amino acid mixture (see Methods for details).

CNO (10 μM) has been shown to interreact with several endogenous biogenic amine GPCRs, including 
the 5-HT2A receptor subtype (35). Interestingly, a recent study suggests that altered 5-HT2A receptor expres-
sion may contribute to defective insulin and glucagon secretion in T2D (36). Since we perifused mouse 
islets with 10 μM CNO, it is possible that CNO also bound to endogenous islet GPCRs, including the 
5-HT2A receptor. However, Figure 4, A and B, convincingly shows that insulin and glucagon release were
similar in CNO-treated control islets versus untreated control islets. This observation strongly suggests that
the potential interaction of  CNO with GPCRs endogenously expressed by mouse islets had no significant
effect on insulin and glucagon secretion under our experimental conditions.
In the in vivo studies, we injected mice with a standard dose of  CNO (1 mg/kg i.p.). In a previous 
study, we monitored CNO plasma levels after i.p. injection of  mice with the same CNO dose (37). Plasma 
CNO levels peaked 15 minutes after CNO injection and then gradually declined throughout the 2-hour 
observation period. We found no significant back-transformation of  CNO to clozapine. Despite the short 
plasma half-life of  CNO in mice, the biological effects that have been observed after acute treatment of  
DREADD-expressing experimental animals usually last for several hours (37, 38). One possibility is that 
CNO tends to accumulate in tissues, including pancreatic islets (37).
In conclusion, the α-GiD mutant mouse line represents what we believe to be an excellent novel tool to 
explore the physiological and pathophysiological roles of  α cell glucagon. In the present study, we provide 
strong evidence that intraislet glucagon signaling is critical for proper GSIS and glucose homeostasis in vivo. 
Our in vitro data indicate that this glucagon activity is primarily due to glucagon-dependent stimulation of  
β cell GLP-1 receptors, both in mouse and human islets. The present study greatly advances our knowledge 
about the in vivo relevance of  intraislet glucagon signaling. These findings could pave the way for the devel-
opment of  novel classes of  antidiabetic drugs that can modulate intraislet cross-talk between α and β cells.
Methods
Drugs. All drugs, antibodies, and mouse models used are listed in Supplemental Table 1.
Mouse maintenance. Mice were fed ad libitum, kept on a 12-hours light/dark cycle, and maintained at 
room temperature (23°C). Mice consumed standard chow (7022 NIH-07 diet, 15% kcal fat, energy density 
3.1 kcal/g, Envigo Inc.).
Generation of  α-GiD mice. Mice that carried the Rosa-CAG-LSL-HA-DREADD-P2A-mCitrine allele (Rosa26-
LSL-hM4Di mice) (10) were crossed with Gcg-CreERT2 mice (11). In Rosa26-LSL-hM4Di mice, the GiD recep-
tor, a CNO-sensitive Gi DREADD(9), is under the transcriptional control of  the strong ubiquitous CAG 
promoter, separated from the DREADD-coding sequence by a floxed stop cassette. GiD expression can be 
switched on by Cre-mediated excision of  the floxed STOP cassette (note that GiD carries an N-terminal, 
extracellular HA-epitope tag). The Gcg-CreERT2 mouse line expresses Cre recombinase specifically in α cells 
without disrupting preproglucagon gene expression. Gcg-CreERT2 mice were initially generated on a mixed 
genetic background (11). We backcrossed the Gcg-CreERT2 mice for 10 generations onto a C57BL/6 back-
ground. In order to induce nuclear Cre activity, we injected the Gcg-CreERT2; Rosa26-LSL-hM4Di mice for 6 
consecutive days with TMX (MilliporeSigma) suspended in corn oil (MilliporeSigma) (2 mg TMX i.p. per 
mouse per day). As outlined in detail in the Results, TMX treatment of  Gcg-CreERT2; Rosa26-LSL-hM4Di mice 
led to the selective expression of  GiD in pancreatic α cells. For this reason, we simply refer to these mice as 
α-GiD mice. For control purposes, we injected Rosa26-LSL-hM4Di mice that lacked the Cre transgene with 
TMX in an identical fashion. These mice did not express the GiD receptor and served as control animals 
throughout the study. All animals used were maintained on a C57BL/6 background.
Figure 6. Glucagon release strongly promotes insulin secretion from WT mouse and human islets via activation of GLP-1 receptors. WT mouse 
pancreatic islets were perifused with 3 and 12 mM of glucose (G3 and G12, respectively) and a physiological amino acid mixture (AAM). Glucagon and 
insulin secretion were monitored continuously throughout experiments and normalized to islet DNA content. (A and B) Glucagon (A) and insulin 
(B) secretion in the presence or absence of Ex-9 (1 μM), a selective GLP-1 receptor antagonist. (C and D) Glucagon (C) and insulin (D) secretion in the 
presence or absence of adomeglivant (Ado; 1 μM), a selective glucagon receptor antagonist. (E and F) Glucagon (E) and insulin (F) secretion in the
presence or absence of a mixture of Ex-9 (1 μM) and Ado (1 μM). (G and H) Studies with isolated human islets. Human islets were perifused with 3 and 
16.7 mM of glucose (G3 and G16.7, respectively), in the presence of AAM. Glucagon (G) and insulin (H) secretion were monitored continuously through-
out experiments. Ex-9 (1 μM) was added 20 minutes before stimulation of islets with G16.7. In the control groups, Ex-9 was omitted from perfusate.
The bar graph in H shows insulin release during the G16.7 perifusion period. Data represent mean ± SEM from 3 or 4 perfusions. *P < 0.05 (2-tailed
Student’s t test). Mouse islets were prepared from male mice (age 12–20 weeks). Data are mean ± SEM (3 or 4 perifusions with 50 mouse islets per 
perifusion chamber; islets from 2 mice were pooled per perifusion experiment).
Mouse genotyping. Gcg-CreERT2 and Rosa26-LSL-hM4Di mice were genotyped by using mouse tail DNA. 
To detect the Gcg-CreERT2 transgene, the following PCR primer pair was used: Cre-F, 5′-CCTGGAAAAT-
GCTTCTGTCCG; Cre-R, 5′-CAGGGTGTTATAAGCAATCCC) (size of  PCR product: 400 bp). The 
presence of  the Rosa26-LSL-hM4Di allele was confirmed by the use of  the following 2 PCR primers: Di-F, 
5′-CGAAGTTATTAGGTCCCTCGAC; Di-R, 5′-TCATAGCGATTGTGGGATGA (size of  PCR prod-
uct: 200 bp). PCR reactions were carried out using standard procedures.
CNO challenge test, glucose tolerance test, and insulin tolerance test. In vivo metabolic tests were performed 
with adult male or female mice (age range, 12–30 weeks) using standard procedures. In brief, to assess 
the in vivo effects of  activating the GiD receptor in α cells, α-GiD mice and their control littermates were 
injected with CNO (1 mg/kg i.p. in saline). CNO was administered to both freely fed mice and mice that 
had been fasted overnight for 12 hours. Blood glucose concentrations were determined using blood col-
lected from the tail vein at defined time points. To study glucose tolerance, mice were fasted overnight for 
approximately 12 hours and then injected with glucose (2 g/kg i.p.), either in the presence or absence of  
CNO (1 mg/kg i.p.). Blood glucose concentrations were determined in the same fashion as in the CNO 
challenge test. For insulin tolerance testing, mice were fasted for approximately 4 hours and then injected 
with human insulin (0.75 U/kg i.p.), either in the presence or absence of  CNO (1 mg/kg i.p.), followed 
by the monitoring of  blood glucose levels. Blood glucose levels were determined using an automated 
blood glucose reader (Glucometer Elite Sensor; Bayer).
Measurement of  plasma glucagon, insulin, GLP-1, GIP, and SST levels. To measure the plasma levels of  sev-
eral key hormones during the various in vivo metabolic tests, blood samples (40–50 μl) collected from the 
tail vein at different time points (0, 5, 15, and 30 minutes) were transferred to EDTA-coated tubes (SAFE-
T-FILL, RAM Scientific) and centrifuged for plasma collection (10,000 g, 10 minutes, 4°C). All hormone 
assays were carried out in the presence of  aprotinin (proteinase inhibitor) and DPP-4 inhibitor (KR-62436 
hydrate; MilliporeSigma). Insulin, glucagon, GLP-1, GIP, and SST plasma levels were determined by using 
commercially available ELISA kits (see the Supplemental Table 1 for details).
Perifusion studies with isolated mouse islets. Mouse pancreatic islets were isolated as described previously (39). 
An automated perifusion system was utilized to dynamically measure glucagon and insulin secretion from 
pancreatic islets (Biorep Perifusion System). A peristaltic pump pushed HEPES-buffered solution (composition 
in mM: 125 NaCl, 5.9 KCl, 2.56 CaCl2, 1.2 MgCl2, 25 HEPES, and 0.1% BSA [pH 7.4]; perifusion rate: 100 
μl/min) through a sample container with the islets immobilized in Bio-Gel P-4 Gel (Bio-Rad). Each perifu-
sion chamber contained 50 islets. The concentrations of the various agents used to induce insulin or glucagon 
secretion are given in the text and/or the figure legends. In perifusion studies, islets were exposed to a physi-
ological AAM of the following composition (final concentrations in mM): 0.88 alanine, 0.38 arginine, 0.076 
aspartate, 0.19 citrulline, 0.24 glutamate, 0.60 glycine, 0.15 histidine, 0.19 isoleucine, 0.32 leucine, 0.74 lysine, 
0.10 methionine, 1.40 ornithine, 0.16 phenylalanine, 0.70 proline, 1.14 serine, 0.54 threonine, 0.15 tryptophan, 
0.40 valine, and 2 glutamine. The AAM and other agents were applied with the HEPES-buffered solution. 
Figure 7. Schematic depicting how glucagon release from α cells stimulates insulin secretion from β cells. (A) In 
WT mouse islets, stimulation of α cells (e.g., by an amino acid mixture [AAM]) promotes the release of insulin from 
adjacent β cells, primarily by activating β cell GLP-1 receptors. Glucagon stimulation of β cell glucagon receptors (GCG 
receptors) is predicted to make a minor contribution to this response. (B) In islets from α-GiD mice, CNO-mediated acti-
vation of the GiD designer receptor inhibits α cell activity, leading to decreased glucagon release, which in turn causes 
reduced insulin secretion from β cells.
Perfusates were collected every minute in 96-well plates for further analysis. The chambers containing the islets 
were kept at 37°C, and the perfusates in the collecting plates were kept at <4°C. Samples were kept at –80°C 
until further analysis. Glucagon and insulin concentrations in the perfusates were determined with a mouse 
glucagon ELISA kit (Mercodia) and an ultrasensitive mouse insulin ELISA kit (Crystal Chem), respectively.
Human islets — source and culture. Human islets were received from the accredited Human Islet Resource 
Center at the University of Pennsylvania and from the Integrated Islet Distribution Program (https://iidp.coh.
org). Islets were obtained from 5 individuals (3 males and 2 females) who were normoglycemic at the time of  
organ isolation. HbA1c values were 5.2%, 5.2%, 4.7%, 6.0%, and 5.7%, respectively. Donors were 13, 35, 39, 
60, and 66 years old, with BMIs of 18.7, 26.9, 34.7, 30.6 and 22.5 kg/m2, respectively. The cold ischemia time 
ranged from 8 to 13 hours. Human islets were then transferred and cultured in the laboratory (14, 40).
Perifusion studies with human islets. Handpicked human islets (500 islets) were placed on a nylon filter in 
a plastic perifusion chamber (MilliporeSigma) and were perfused with a flow rate of  1 ml/min (41). The 
perifusion apparatus consisted of  a computer-controlled low-pressure chromatography system (Bio-Rad 
Econo System) that allowed programmable rates of  flow and glucose concentrations in the perfusate, a 
water bath (37°C), and a fraction collector (Bio-Rad; model 2128). The perifusion solution consisted of  
Krebs buffer (pH 7.4) of  the following composition (in mM): 114 NaCl, 5 KCl, 24 NaHCO3, 1 MgCl2, 2.2 
Ca2+, 1 Pi, 10 HEPES (pH 7.4), and 0.25 % BSA equilibrated with 95% O2 and 5% CO2. After a 30-minute 
washout period, a physiological AAM (a mixture of  19 amino acids; 4 mM total) was added to stimulate 
glucagon secretion (14), followed by the consecutive addition of  3 and 16.7 mM glucose for 40 and 25 
minutes, respectively (AAM was present in the perifusion solution throughout the entire experiment). In 
the experimental group, Ex-9 (1 μM) or a mixture of  Ex-9 and Ado (1 μM each) were added prior to the 
addition of  16.7 mM glucose. In the control groups, these drugs were omitted from the perfusate.
Western blotting studies. Immunoblotting studies were carried out by using standard procedures (39). 
In brief, mouse tissues were lysed in RIPA buffer containing protease and phosphatase inhibitor cocktails 
(Roche). Protein lysates were subjected to SDS-PAGE without heat denaturation. About 10 μg protein 
was loaded per lane. Immunoreactive proteins were visualized by using SuperSignal West Pico Chemilu-
minescent Substrate (Pierce) and an Azure C600 gel imaging system (Azure Biosciences). The antibod-
ies that were used are listed in Supplemental Table 1. Primary and secondary antibodies were diluted 
1:1,000 and 1:2,000, respectively.
Immunofluorescence and histological studies. Immunofluorescence microscopic studies were performed 
using paraffin-embedded mouse islet sections employing standard procedures. Briefly, pancreata were fixed 
overnight with 4% paraformaldehyde/PBS and embedded in paraffin. After deparaffinization, tissue sec-
tions were subjected to antigen retrieval using IHC-Tek epitope retrieval solution (IHC WORLD) in IHC-
Tek epitope retrieval steamer (IHC WORLD) for 35 minutes. Tissue sections were blocked in PBS-based 
IHC-Tek Antibody Diluent (IHC WORLD) for insulin and HA coimmunostaining or in 5% goat serum 
in PBS for glucagon and HA coimmunostaining for 1 hour and incubated overnight at 4°C with a mixture 
of  guinea pig anti-insulin and rabbit anti-HA antibody/mouse anti-glucagon and rabbit anti-HA antibody 
in blocking medium. After thorough washing of  the tissue sections, the insulin, glucagon, and anti-HA 
primary antibodies were detected by Alexa Fluor 555 goat anti-guinea pig secondary antibody, Alexa Fluor 
555 goat anti-mouse secondary antibody, and Alexa Fluor 488 goat anti-rabbit secondary antibody, respec-
tively (for antibody details, see Supplemental Table 1). All sections were counterstained and mounted using 
ProLong Gold antifade reagent with DAPI (P36931, Thermo Fisher Scientific). Slides were imaged on a 
Keyence digital microscope (BZ-9000) with a CFI Plan Apo l ×40 lens.
Statistics. Data are expressed as mean ± SEM for the indicated number of  observations. Prior to per-
forming specific statistical tests, we performed tests for normality and homogeneity of  variance. Data were 
then tested for statistical significance by mixed-effects repeated-measures ANOVA for differences after 
injection using R software (version 3.5) or by a 2-tailed unpaired Student’s t test, as appropriate. A P value 
of  less than 0.05 was considered statistically significant.
Study approval. All animal studies were approved by the National Institute of  Diabetes and Digestive 
and Kidney Diseases Institutional Animal Care and Use Committee. The University of  Pennsylvania Insti-
tutional Review Board has exempted research in human islets from ethical review because the islets were 
received from deceased, deidentified organ donors. All pancreata were from deceased donors after having 
obtained consent from their families through UNOS (United Network for Organ Sharing).
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